Coronary Circulation and Oxygen Demand-Supply Imbalance Under Anesthesia

1. ANATOMY OF THE CORONARY CIRCULATION

• Left coronary artery (LCA): Divides into the left anterior descending (LAD) and circumflex (Cx) arteries. The LAD supplies the anterior wall and septum of the left ventricle; the Cx supplies the lateral and posterior LV wall.
• Right coronary artery (RCA): Traverses the right AV groove, supplying the right ventricle via acute marginal branches. In 80-90% of people ("right dominant"), the RCA gives rise to the posterior descending artery (PDA) that supplies the inferior LV. The AV node artery arises from the dominant vessel; the SA node artery arises from the RCA in 55% of individuals.
• Venous drainage: ~75% of left ventricular coronary venous blood returns via the coronary sinus to the right atrium. Right ventricular blood returns largely via anterior cardiac veins directly to the right atrium. A small amount drains through thebesian veins directly into all cardiac chambers.
• Resting coronary blood flow averages ~70 mL/min/100 g (~225 mL/min total), representing 4-5% of cardiac output.

2. PHASIC NATURE OF CORONARY BLOOD FLOW

• It is furthest from epicardial supply vessels
• Intramural pressure is highest in the subendocardium
• Its flow reserve is recruited first and exhausted soonest under stress

3. DETERMINANTS OF MYOCARDIAL OXYGEN SUPPLY

3a. Coronary Blood Flow

• Metabolic (local) autoregulation - the dominant controller. Hypoxia and adenosine cause coronary arteriolar vasodilation. Carbon dioxide (from Krebs cycle), reactive oxygen species, and nitric oxide (NO) from eNOS are upstream mediators. K_ATP channels (responding to falling ATP) cause smooth muscle hyperpolarization and vasodilation.
• Autoregulation of flow: Coronary blood flow is maintained constant over a wide range of perfusion pressures (approximately 60-130 mmHg). Coronary flow reserve (CFR) is the ratio of maximum achievable flow to resting flow - normally 4-6x. As stenosis worsens, CFR narrows.
• Endothelium-derived factors: Prostacyclin (PGI2) causes vasodilation and inhibits platelet aggregation. Endothelin-1 causes vasoconstriction but is normally counterbalanced by NO. Atherosclerosis impairs NO release, reducing vasodilatory capacity.
• Neural control: Sympathetic stimulation (alpha-1) causes mild direct vasoconstriction, but beta-2 stimulation and the dominant metabolic vasodilation generally prevail. Net effect during stress is vasodilation driven by increased metabolic demand.

3b. Arterial Oxygen Content

• Hemoglobin concentration is the primary determinant
• The oxyhemoglobin dissociation curve position matters: leftward shift (alkalosis, hypothermia, low 2,3-DPG) decreases oxygen release to tissues even at adequate delivery
• Dissolved oxygen contributes minimally at normal PaO2

4. DETERMINANTS OF MYOCARDIAL OXYGEN DEMAND

5. HOW ANESTHESIA DISRUPTS THE OXYGEN BALANCE

5a. Hemodynamic Effects

• Reduced aortic diastolic pressure decreases CPP
• Common causes: volatile anesthetic vasodilation, neuraxial sympathectomy, hypovolemia, myocardial depression, aortocaval compression

• A dual threat: increases oxygen demand AND reduces diastolic time, shrinking the window for coronary perfusion
• Even small heart rate increases during the perioperative period are clinically significant, especially with underlying CAD
• This is the physiological basis for beta-blocker use as anti-ischemic therapy

• Raises afterload and wall tension, sharply increasing MVO2
• Paradoxically, it may increase CPP but the demand side usually predominates

• From myocardial depression, volume loading, or ischemia itself
• Directly compresses subendocardial vessels, worsening the most vulnerable zone

5b. Respiratory and Hematological Factors

• Hypoxia - reduces arterial oxygen content; also a direct coronary vasodilator (compensatory) but fails when flow is limited by stenosis
• Anemia - reduced oxygen-carrying capacity; critical in patients with limited coronary reserve
• Alkalosis / Hypothermia - leftward shift of oxygen-hemoglobin dissociation curve, impairs O2 delivery to myocardium even when hemoglobin is saturated
• Hypercapnia - coronary vasodilator but also causes sympathetic activation (raises demand)

5c. Sympathetic Nervous System Activation

• Coronary vasoconstriction (alpha-1 on large arteries)
• Tachycardia and hypertension (increased demand)
• In diseased vessels with impaired endothelium, vasoconstriction can be paradoxically exaggerated

6. VOLATILE ANESTHETIC AGENTS AND CORONARY CIRCULATION

Coronary Steal (Isoflurane Controversy)

• Sevoflurane is approximately half as potent a coronary vasodilator as isoflurane
• Desflurane - when given without opioids at high concentrations in CAD patients, has caused significant ischemia, necessitating beta-blockers. Rapid increases in inspired desflurane concentration trigger sympathetic activation with tachycardia and hypertension - both unfavorable for the supply-demand balance
• Determinants of myocardial oxygen supply and demand, rather than the choice of volatile agent, are of greater importance to patient outcomes

Anesthetic Preconditioning (Cardioprotection)

• They diffuse through myocardial cell membranes and alter mitochondrial electron transport, generating reactive oxygen species as triggers
• This activates Protein Kinase C → K_ATP channel opening
• ~30-40% of cardioprotection relates to reduced mitochondrial calcium loading
• Opioids (especially at high doses) maintain the O2 supply-demand ratio in cardiac surgery as well as or better than inhalation-based techniques; they also exhibit delta- and kappa-opioid receptor mediated preconditioning

7. PERIOPERATIVE MYOCARDIAL ISCHEMIA (PMI)

1. Plaque rupture and thrombosis - acute coronary syndrome pattern, often presenting as STEMI
2. Demand-supply imbalance - more common perioperatively; typically subendocardial, NSTEMI pattern

• Hypotension, hypertension, tachycardia
• Bleeding and anemia
• Hypoxia and hypothermia
• Coronary vasoconstriction from catecholamines

8. MONITORING FOR ISCHEMIA UNDER ANESTHESIA

ECG Monitoring

• Multilead ST-segment analysis - leads II and V5 together detect >80% of ischemic events; all five leads detect >95%
• ST depression ≥1 mm (subendocardial ischemia - demand-type)
• ST elevation (transmural ischemia / spasm)
• T-wave inversion, new LBBB, arrhythmias

Transesophageal Echocardiography (TEE)

• Regional wall motion abnormalities (RWMA) are the earliest sign of ischemia - appearing before ECG changes
• Segmental hypokinesia, akinesia, or dyskinesia in a coronary territory indicates ischemia
• Indispensable in cardiac surgery and high-risk noncardiac surgery

9. MANAGEMENT PRINCIPLES

1. High-risk surgery (intraperitoneal, intrathoracic, suprainguinal vascular)
2. History of ischemic heart disease
3. History of congestive heart failure
4. History of cerebrovascular disease
5. Insulin-dependent diabetes
6. Serum creatinine >2.0 mg/dL

SUMMARY DIAGRAM (Conceptual)

CORONARY OXYGEN BALANCE UNDER ANESTHESIA
                    │
        ┌───────────┴───────────┐
    O2 SUPPLY               O2 DEMAND
        │                       │
  ┌─────┴──────┐         ┌──────┴──────┐
  CBF  ×  CaO2         HR × WallTension × Contractility
   │      │               │         │
  CPP=   Hb, SaO2       Anesthetic Sympathetic
 AoD-   Leftward shift   depth    activation
 LVEDP  → impairs O2    Opioids   (laryngoscopy,
        release         reduce    light plane)
   │                    demand
 Tachycardia = ↓diastole
 Hypotension = ↓AoD
 ↑LVEDP = ↓CPP
 → SUBENDOCARDIAL ISCHEMIA

CITATIONS

• Miller's Anesthesia, 10th Edition - Determinants of Myocardial Oxygen Supply and Demand; Coronary Circulation and Myocardial Ischemia
• Barash's Clinical Anesthesia, 9th Edition - Coronary Physiology; Coronary Steal, Myocardial Ischemia, and Cardiac Outcome; Cardioprotection from Volatile Anesthetics
• Guyton & Hall Textbook of Medical Physiology - Coronary Circulation, Control of Coronary Blood Flow
• Costanzo Physiology, 7th Edition - Coronary Circulation
• Sabiston Textbook of Surgery - Perioperative Myocardial Ischemia and Infarction

Context-Sensitive Half-Time: Concept, Propofol vs Fentanyl in Clinical Anesthesia

1. THE PROBLEM WITH ELIMINATION HALF-LIFE (t½)

• It does not account for drug redistribution from peripheral tissue compartments back into the plasma after the infusion ends
• It does not account for how long the infusion has been running (saturation of peripheral compartments)
• It gives a fixed number that is infusion-duration independent, which is misleading

2. DEFINITION OF CONTEXT-SENSITIVE HALF-TIME (CSHT)

• Calculated by computer simulation of multicompartmental pharmacokinetic models
• A function of both distribution (drug returning from peripheral compartments) and elimination (hepatic/other clearance)
• Expressed as a curve plotting CSHT (y-axis, minutes) against infusion duration (x-axis, hours) - not a single number

3. MULTICOMPARTMENT PHARMACOKINETIC FRAMEWORK

DOSE → [Central Compartment (V1)] ← → [Rapid Peripheral (V2)]
           Plasma / Blood                Muscle, viscera
                 ↕
           [Slow Peripheral (V3)]
                 Fat, bone
                 ↕
           Elimination (clearance)

• Drug distributes from central compartment → peripheral compartments (V2, V3)
• Plasma concentration is buffered by this outward distribution

• Drug flows back from peripheral compartments → central compartment (down the concentration gradient)
• This return flow replaces drug eliminated from plasma, slowing the fall in plasma concentration
• The longer the infusion, the more drug is stored in peripheral compartments, the more returns = the longer the CSHT

4. THE CLASSIC CSHT GRAPH (Hughes et al., 1992)

1. All drugs show increasing CSHT with longer infusions - but to vastly different degrees
2. Fentanyl shows the steepest and most dramatic rise - approaching 280+ minutes after an 8-hour infusion
3. Propofol shows a nearly flat curve - remaining below ~40 minutes even after 8+ hours of infusion
4. Thiopental rises substantially but more slowly than fentanyl
5. Sufentanil stays far below fentanyl despite having a longer elimination t½ - this counterintuitive finding is a key teaching point

5. PROPOFOL: CLINICAL PHARMACOKINETICS AND CSHT

Why Propofol has a Favorable (Low) CSHT

• Propofol undergoes rapid, extensive hepatic metabolism (glucuronidation and hydroxylation)
• Its clearance (1.5-2.0 L/min) exceeds hepatic blood flow - indicating extrahepatic metabolism as well (lung, kidney, gut)
• Drug returning from peripheral compartments is rapidly cleared before it can accumulate in plasma
• Net effect: the return of drug from tissues does not significantly impede plasma concentration decay

• Although propofol is highly lipophilic, the rate at which it returns from deep peripheral compartments (fat) is slow
• Combined with rapid elimination, even the drug that does return is immediately removed

Propofol in TIVA (Total Intravenous Anesthesia)

• Propofol's short CSHT is the primary reason it is the preferred drug for TIVA and target-controlled infusion (TCI)
• Its CSHT profile allows confident prediction of awakening regardless of infusion duration
• Used for induction (1-2.5 mg/kg IV) followed by maintenance infusion (25-75 mcg/kg/min)
• Has additional advantages: antiemetic properties, smooth emergence, reduced postoperative nausea/vomiting (PONV)

Effect-Site Equilibration (ke0) of Propofol

• Propofol has a short t½ ke0 (rapid equilibration between plasma and brain/effect site)
• This means plasma concentration changes are quickly reflected in clinical effect - making it easily titratable
• This short ke0 also means rapid onset of consciousness loss after bolus induction

6. FENTANYL: CLINICAL PHARMACOKINETICS AND CSHT

Why Fentanyl has an Unfavorable (High) CSHT

• Fentanyl is highly lipophilic (octanol:water partition coefficient ~816)
• Volume of distribution at steady state (Vdss) is very large (~4-6 L/kg)
• Rapid initial redistribution into fat, muscle, and other peripheral tissues causes the short clinical duration after a single bolus dose - NOT elimination
• This is redistribution, not metabolism - the drug is still present in the body in large amounts

• As infusion continues, peripheral compartments (especially fat) become progressively saturated
• Once saturation is reached, redistribution can no longer act as a buffer
• When infusion stops, enormous amounts of stored fentanyl return from peripheral compartments to plasma
• Hepatic clearance (~1 L/min) is insufficient to keep pace with this return
• Result: plasma concentration falls extremely slowly

Clinical Implications of Fentanyl's CSHT

• Short cases: Fentanyl boluses are excellent - redistribution terminates effect rapidly, drug is predictable
• Long infusions (>2-3 hours): Fentanyl is a poor choice as a continuous infusion analgesic component - emergence will be delayed, respiratory depression unpredictable
• ICU sedation with fentanyl infusions causes significant drug accumulation; patients may remain obtunded for many hours after the infusion is stopped

7. CSHT DOES NOT EQUAL TIME TO RECOVERY

• If a patient is maintained at a concentration far above the awakening concentration (e.g., for cardiac surgery), even a drug with a short CSHT will take longer to produce awakening
• If maintained just above the awakening threshold, the 50% CSHT will nearly equal the time to awakening (Fig 30-5, Barash)

• CSHT reflects plasma concentration, but awakening is determined by effect-site (brain) concentration
• There is always a time lag between plasma and brain concentration (the hysteresis loop)
• Fentanyl has a t½ ke0 of 6.4 minutes - slow plasma-to-brain equilibration
• Alfentanil has a t½ ke0 of 1.1 minutes - rapid equilibration
• Propofol has a short t½ ke0 - making it rapidly titratable
• For a brief single stimulus (e.g., intubation), alfentanil is logically superior to fentanyl as the EEG effect closely mirrors plasma levels

• CSHT describes 50% reduction - but if 80% or 90% reduction is needed to cross the awakening threshold, CSHT underestimates recovery time
• "Context-sensitive time to recovery" is a related concept that maps the percentage decline needed for the specific clinical endpoint

8. REMIFENTANIL - THE CSHT IDEAL

• Contains an ester linkage in its structure
• Metabolized by non-specific plasma and tissue esterases (not liver-dependent)
• CSHT is essentially constant and independent of infusion duration - approximately 3-4 minutes regardless of whether the infusion ran for 30 minutes or 10 hours
• This makes it ideal for prolonged surgery requiring rapid, predictable offset
• Major limitation: no residual analgesia after stopping infusion - multimodal analgesia must be planned preemptively

9. COMPARATIVE SUMMARY TABLE

10. CLINICAL PRACTICE IMPLICATIONS

For Propofol:

1. TIVA: Safe for short and long cases; expected emergence is predictable regardless of case duration
2. TCI (Target Controlled Infusion): Pharmacokinetic models (Marsh, Schnider) exploit the stable CSHT to allow effect-site targeting
3. Day surgery / ambulatory anesthesia: Drug of choice due to rapid, predictable recovery
4. Caution: Propofol has no analgesic properties; must always be combined with opioid or regional analgesia

For Fentanyl:

1. Bolus dosing for short cases: Fentanyl remains an excellent opioid - a single 1-2 mcg/kg bolus gives 20-30 min analgesia via redistribution; duration predictable
2. Avoid as continuous infusion for cases >1-2 hours: Use sufentanil, alfentanil, or preferably remifentanil
3. ICU/long TIVA: Fentanyl infusions cause significant accumulation; plan for postoperative respiratory support
4. Synergy with propofol: Fentanyl markedly reduces propofol CP50 (concentration needed to ablate response to skin incision and other stimuli), allowing lower propofol doses - this synergy is routinely exploited in TIVA

The "Balanced" Anesthesia Principle:

CITATIONS

• Barash's Clinical Anesthesia, 9th Edition - Context-Sensitive Half-Time; How Does CSHT Relate to Recovery?; Pharmacokinetics: General Principles for Intravenous Anesthetics
• Miller's Anesthesia, 10th Edition - Pharmacokinetics and Pharmacodynamics of Opioids; Total Intravenous Anesthesia with Propofol and Opioids
• Katzung's Basic and Clinical Pharmacology, 16th Edition - Pharmacokinetics (Anesthetics)
• Hughes MA, Glass PSA, Jacobs JR. Context-sensitive half-time in multicompartmental pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology. 1992;76:334-341. (Original paper defining the concept)

Renal Autoregulation and its Relevance During Perioperative Fluid Therapy

1. INTRODUCTION: WHY THE KIDNEY NEEDS AUTOREGULATION

2. DEFINITION OF RENAL AUTOREGULATION

• Operates over a MAP range of approximately 70-180 mmHg (the autoregulatory plateau)
• Below MAP ~70 mmHg, autoregulation fails and RBF/GFR fall proportionally with pressure
• Above MAP ~180 mmHg, autoregulation is overwhelmed and flow rises
• A denervated (transplanted) kidney autoregulates as well as an intact kidney - confirming its intrinsic, non-neural nature

3. MECHANISMS OF RENAL AUTOREGULATION

Mechanism 1: Myogenic Response (Fast - seconds)

1. ↑ Renal perfusion pressure → stretches the wall of the afferent arteriole
2. Mechanical stretch opens mechanosensitive (stretch-activated) cation channels → membrane depolarization
3. Depolarization activates voltage-gated L-type calcium channels → Ca²⁺ influx into smooth muscle cells
4. ↑ Intracellular Ca²⁺ → smooth muscle contraction → afferent arteriolar vasoconstriction
5. ↑ Resistance offsets ↑ pressure → RBF remains constant

• Converse applies with decreased pressure: reduced stretch → smooth muscle relaxation → vasodilation → ↓ resistance

Mechanism 2: Tubuloglomerular Feedback (TGF) - Slower (20+ seconds)

1. ↑ MAP → ↑ RBF → ↑ GFR → ↑ filtrate delivery to the thick ascending limb
2. ↑ NaCl delivery to the macula densa
3. Macula densa cells increase NaCl uptake via furosemide-sensitive Na⁺-K⁺-2Cl⁻ cotransporter (NKCC2)
4. This triggers ATP release into the extracellular space
5. ATP → metabolized to adenosine in the extracellular space → acts on adenosine A1 receptors on afferent arteriolar smooth muscle → vasoconstriction
6. ↑ Afferent arteriolar resistance → ↓ glomerular hydrostatic pressure → ↓ GFR back to normal

• ↓ NaCl delivery → less macula densa activation → afferent arteriolar vasodilation + ↑ renin release → angiotensin II → efferent arteriolar constriction → maintains glomerular hydrostatic pressure → preserves GFR

• Angiotensin II: Sensitizes TGF (enhances its responsiveness)
• Nitric oxide (NO): Blunts TGF (vasodilatory counter-regulation); NO is not essential for TGF but modulates the plateau
• Prostaglandins: Vasodilatory prostaglandins (PGI2, PGE2) counteract excessive vasoconstriction - clinically relevant for NSAIDs

Mechanism 3: Glomerulotubular Balance (Supplementary)

• A constant fraction (~67%) of filtered water and solute is reabsorbed in the proximal tubule regardless of GFR
• This prevents the distal segments of the nephron from being overwhelmed during sudden GFR increases
• Protects distal tubular concentrating mechanisms even during rapid hemodynamic changes

4. LIMITS OF AUTOREGULATION AND WHEN IT FAILS

5. RENAL RESPONSE TO VOLUME DEPLETION

a) Sympathetic Nervous System Activation

• Renal sympathetic nerves are richly distributed to afferent and efferent arterioles and tubular cells
• Catecholamine release (especially norepinephrine) causes afferent arteriolar constriction - reducing RBF and GFR
• Also directly increases tubular sodium reabsorption via alpha-adrenergic receptors on tubular cells
• α2-adrenergic activity reduces the glomerular ultrafiltration coefficient

b) Renin-Angiotensin-Aldosterone System (RAAS)

• Hypovolemia → ↓ perfusion pressure at the JGA → ↑ renin release (from juxtaglomerular cells)
• ↓ NaCl delivery to macula densa → also triggers ↑ renin
• Renin → angiotensinogen → angiotensin I → ACE → angiotensin II
• Ang II preferentially constricts the efferent arteriole >> afferent arteriole at moderate volume depletion → maintains GFR (and glomerular hydrostatic pressure) despite reduced RBF (filtration fraction increases)
• In severe volume depletion, Ang II drives afferent constriction too → GFR falls
• Ang II also directly stimulates proximal tubular Na⁺-H⁺ exchangers → sodium reabsorption
• Ang II triggers aldosterone release → Na⁺ retention in collecting duct

c) Antidiuretic Hormone (AVP/ADH)

• Hypovolemia is a potent stimulus for AVP release (even overriding osmolarity signals)
• AVP causes: peripheral vasoconstriction + water reabsorption at collecting duct
• Urine becomes highly concentrated (osmolality up to 1200 mOsm/kg) with virtually no sodium (<10 mEq/L) - the hallmark of prerenal azotemia

6. PERIOPERATIVE FLUID THERAPY: THE CLINICAL RELEVANCE

Why the Perioperative Period is High Risk for Renal Autoregulatory Failure

Principles of Perioperative Fluid Therapy Informed by Autoregulation

A. Maintain MAP Within the Autoregulatory Plateau

• In normal patients: keep MAP ≥65-70 mmHg
• In chronic hypertensives: their lower limit may be 90-100 mmHg; a MAP of 70 mmHg that seems "adequate" for normal patients may cause renal ischemia in them
• Clinical implication: Do not accept "permissive hypotension" in hypertensive patients or those with renal disease

B. Correct Preoperative Hypovolemia

• Assess volume status before induction: history, urine output, skin turgor, HR, BP, dry mucous membranes
• Resuscitate with appropriate crystalloid or colloid before anesthesia where deficit is significant
• Correcting hypovolemia before vasodilation of anesthesia prevents the combined insult of low MAP + high RAAS/sympathetic tone on renal perfusion

C. Goal-Directed Fluid Therapy (GDFT)

• Liberal fluid strategies (risk: interstitial edema, impaired bowel recovery, dilutional coagulopathy, pulmonary edema)
• Restrictive fluid strategies (risk: hypovolemia, renal hypoperfusion, AKI)

• Stroke volume (SV) optimization via dynamic fluid responsiveness indices (pulse pressure variation, stroke volume variation, passive leg raise)
• Maintain cardiac output sufficient to meet end-organ demand
• Target urine output ≥0.5 mL/kg/hr as a crude index of renal perfusion (though intraoperative oliguria alone does not mandate aggressive fluid boluses - this remains debated)

D. The Importance of the "Two-Hit" Concept

• Hit 1: Hypovolemia + baseline CKD
• Hit 2: Intraoperative hypotension + nephrotoxic drug (aminoglycoside, contrast, NSAID)
• Hit 3: Sepsis + prolonged low MAP

E. Specific Considerations for Medications

• NSAIDs: Block vasodilatory prostaglandins that normally counteract angiotensin II vasoconstriction at the afferent arteriole. In the volume-depleted patient with high RAAS activity, removing this prostaglandin protection unmasks unopposed vasoconstriction → precipitous ↓ GFR. Avoid or minimize perioperatively, especially in elderly, CKD, hypovolemic, or cardiac failure patients.
• ACE inhibitors/ARBs: In low-volume states, efferent arteriolar tone maintained by Ang II is the last defense of GFR. ACE-I/ARB blockade removes this protection. Consider holding on the day of major surgery (especially cardiac, aortic, or high-blood-loss procedures).
• Vasopressors: When hypotension is driven by vasodilation (neuraxial anesthesia, anesthetic agents), vasopressors (phenylephrine, norepinephrine) are preferable over excessive fluid to restore MAP and renal perfusion without the harms of fluid overload.

F. Markers of Adequacy of Renal Perfusion

7. HYPOVOLEMIA RESPONSE SUMMARY: SCHEMATIC

HYPOVOLEMIA / ↓ MAP
        │
   ┌────┴────────────────────────────┐
   │                                 │
Sympathetic activation            RAAS activation
↓ RBF (afferent constriction)     Ang II: efferent > afferent constriction
↑ Tubular Na reabsorption         → GFR preserved initially
   │                               → Severe: GFR falls
   └────────────────┬──────────────┘
                    │
                 AVP release
              Water retention
              Concentrated urine
                    │
         [PRERENAL AZOTEMIA]
                    │
           If not corrected:
         [ISCHEMIC ATN - irreversible]

8. SPECIAL CLINICAL SCENARIOS

Chronic Hypertension

• Autoregulatory curve is right-shifted - lower limit now ~90-100 mmHg
• Seemingly "normal" MAP of 65-75 mmHg can cause renal ischemia
• Intraoperative MAP should ideally be maintained within 20% of the patient's baseline preoperative MAP

Diabetic Nephropathy

• Afferent arteriolar disease impairs myogenic response
• Glomerular hyperfiltration present at baseline; RAAS chronically activated
• These patients have very narrow autoregulatory range and are extremely sensitive to any perioperative hypotension

Cardiac Surgery (CPB)

• Non-pulsatile flow during cardiopulmonary bypass disrupts TGF signaling
• Hemodilution reduces viscosity (beneficial for flow) but also reduces oxygen carrying capacity
• Mean perfusion pressure on CPB should target ≥70-80 mmHg to maintain autoregulatory reserve

Septic AKI

• Endothelial NO dysregulation impairs autoregulation
• Microvascular injury causes heterogeneous cortical ischemia despite normal or elevated cardiac output
• Fluid therapy alone is insufficient; restoration of MAP with vasopressors is equally important

9. SUMMARY: KEY EXAMINATION POINTS

CITATIONS

• Miller's Anesthesia, 10th Edition - Renal Autoregulation; Renal Control of Intravascular Volume; Perioperative AKI
• Brenner and Rector's The Kidney - Intrinsic Mechanisms: Renal Autoregulation; Prerenal Acute Kidney Injury
• Comprehensive Clinical Nephrology, 7th Edition - Autoregulation of RBF and GFR; Renal Autoregulation
• Guyton & Hall Textbook of Medical Physiology - Autoregulation of GFR and Renal Blood Flow; Importance of GFR Autoregulation
• Costanzo Physiology, 7th Edition - Autoregulation of Renal Blood Flow